These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2214256)

  • 1. Synergy of OK-432 and recombinant interleukin 2 in the antitumor immunity induction and the cytotoxic T-lymphocyte generation.
    Ujiie T
    Jpn J Exp Med; 1990 Jun; 60(3):85-92. PubMed ID: 2214256
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
    Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
    Ujiie T
    Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 and IL-4 can co-modulate the generation of cytotoxic T cells through CD8- CD4- splenic lymphocytes.
    Good MF; Powell LW; Halliday JW
    Immunology; 1989 Jun; 67(2):225-30. PubMed ID: 2568977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable long-term induction of perforin-positive CD8+ T cells in gut by oral administration of streptococcal preparation OK-432.
    Mino N; Naomoto Y; Shirakawa Y; Matsuoka J; Nobuhisa T; Gunduz M; Noma K; Nagatsuka H; Kobayashi M; Yamatsuji T; Haisa M; Gochi A; Tanaka N
    Int J Mol Med; 2004 Nov; 14(5):801-6. PubMed ID: 15492848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
    Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
    Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
    Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
    Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
    Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
    Dröge W; Moyers C; Wehrmaker A; Schmidt H; Panknin S; Männel D; Falk W
    J Immunol; 1984 Jun; 132(6):2749-59. PubMed ID: 6233360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin.
    Iwata H; Nagano T; Toyo-oka K; Hirose H; Hamaoka T; Fujiwara H
    Transplant Proc; 1994 Apr; 26(2):851-4. PubMed ID: 7513476
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
    Fujioka T; Ishikura K; Tanji S; Okamoto T; Koike H; Aoki H; Ohhori T; Kubo T
    Int J Immunopharmacol; 1990; 12(4):419-26. PubMed ID: 2391188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
    Suzuki R; Suzuki S; Ebina N; Kumagai K
    J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin.
    Dziarski R
    J Immunol; 1989 Jul; 143(1):356-65. PubMed ID: 2471741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of nonspecific killer cells by interleukin 2-containing supernatants.
    Teh HS; Yu M
    J Immunol; 1983 Oct; 131(4):1827-33. PubMed ID: 6194216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: combination effect of OK-432 and recombinant lymphokines.
    Nanjo M; Moriya Y; Hashimoto S; Kataoka M; Saito M; Yoshida T; Ishida N
    Int J Immunopharmacol; 1991; 13(2-3):205-15. PubMed ID: 1906439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.